The burgeoning popularity of retatrutide, initially for metabolic conditions, is creating significant attention within the UK , prompting a notable shift in peptide trends. Access these medications remains a complex landscape, with National Health Service provision currently limited and independent providers offering treatment at a higher cost . Qu